biomodal
biomodal is a UK-based life-sciences tools company that commercializes proprietary 6-base genome sequencing kits and software, enabling simultaneous detection of canonical DNA bases plus 5mC and 5hmC epigenetic modifications for academic, pharmaceutical, and clinical-research customers.
- Company typePrivate
- Founded2013
- HeadquartersChesterford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What biomodal does
biomodal (formerly Cambridge Epigenetix until a 2023 rebrand) is a UK-based life-sciences tools company founded in 2013 by Prof. Sir Shankar Balasubramanian and Bobby Yerramilli-Rao. The company has developed a proprietary hairpin-adaptor chemistry that enables simultaneous sequencing of all four canonical DNA bases (A, C, G, T) together with the two principal epigenetic modifications, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), producing what the company markets as a 6-base genome from a single 5ng DNA sample in a single experiment at Q40+ base-call accuracy. Productized under the duet multiomics solution brand, the portfolio includes the duet evoC kit (true 6-base resolution), the duet +modC kit (5-base resolution), the duet UDIs multiplex indexing kits, the duet post-sequencing analysis software, and the modality XPLR low-code analysis software.
Revenue is generated primarily through quote-based sales of consumable kits and software to academic institutions, cancer research hospitals, pharmaceutical and biotech R&D groups, and clinical laboratories. Additional monetization channels include a Certified Service Provider network of 8 validated service organizations across the US, Canada, Australia, and Germany; OEM and white-label partnerships via the Custom Solutions program; and licensing/royalty arrangements associated with tailored assay development. biomodal operates a 51–100 person team headquartered at Chesterford Research Park near Cambridge, UK, with a US office in Carlsbad, California, and was backed by a $98 million financing in 2021 from GV, Temasek, Syncona, Ahren, and New Science Ventures. Customers include the British Columbia Cancer Centre, Peter MacCallum Cancer Centre, Vanderbilt University Medical Center, University College London, Johns Hopkins, the National Cancer Institute, Medical University of Graz, and La Jolla Institute for Immunology, spanning cancer research, neurodegenerative disease, aging, liquid biopsy, and precision-medicine applications.
biomodal firmographics
Firmographics- Name
- biomodal
- Legal name
- biomodal
- Website
- https://biomodal.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- biomodal is a UK-based life-sciences tools company that commercializes proprietary 6-base genome sequencing kits and software, enabling simultaneous detection of canonical DNA bases plus 5mC and 5hmC epigenetic modifications for academic, pharmaceutical, and clinical-research customers.
- Ownership category
- akta.pro rank
biomodal industry classification
Industry- Product category
- DNA Sequencing Tools
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Epigenomics & Chromatin Profiling Services (HLAGANAF)
Keywords
Where biomodal is headquartered
LocationHeadquarters
- HQ city
- Chesterford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
biomodal business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Others
Revenue model
- duet evoC product sales: Sale of duet multiomics solution evoC kits (8-reaction kit product code 6205, 24-reaction kit product code 6206) that include the duet evoC assay library preparation reagents and duet software for genetic and epigenetic analysis.
- duet +modC product sales: Sale of duet multiomics solution +modC kits (8-reaction kit product code 5205, 24-reaction kit product code 5206) for customers requiring 5-base resolution (canonical bases + modified C) without distinguishing 5mC from 5hmC.
- modality XPLR software: Software for analyzing 6-base sequencing data. Bundled with duet kits but also available as standalone product for processing and visualizing multiomic data.
- Custom solutions and OEM partnerships: Partner with customers to create tailored workflows, kits, and integrated solutions including purpose-built assay development, tailored product optimization, flexible formatting, and co-branded or white-label commercial products.
- Certified Service Provider network: Validated service organizations worldwide offer duet multiomics sequencing services using biomodal's technology, expanding market reach through a channel model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | duet multiomics solution evoC 8-reaction kit |
| Unit Pricing | Pay-as-you-go | duet multiomics solution evoC 24-reaction kit |
| Unit Pricing | Pay-as-you-go | duet multiomics solution +modC 8-reaction kit |
| Unit Pricing | Pay-as-you-go | duet multiomics solution +modC 24-reaction kit |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
biomodal product offering
Product offeringCore offering
biomodal develops and sells the duet multiomics solution, a sequencing chemistry and software platform that simultaneously reads the four canonical DNA bases together with the epigenetic modifications 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) from a single low-input DNA sample in a single workflow. Its commercial products are the duet evoC kit (true 6-base genome, 5ng input) and the duet +modC kit (5-base genome, 10ng input), supported by duet software for post-sequencing analysis and the modality XPLR software for multiomic data exploration, all compatible with Illumina and Element Biosciences sequencers.
Product overview
biomodal offers a portfolio of multiomics products centered on the duet multiomics solution platform for 6-base genome sequencing. The core offerings include duet multiomics solution evoC (distinguishes 5mC and 5hmC for true 6-base genome) and duet multiomics solution +modC (detects modified cytosine alongside genetic bases). Supporting these assays are duet software for post-sequencing analysis (deployable on-premises or cloud) and modality XPLR software for visualization and differential analysis. Custom solutions are available for partners requiring tailored workflows. The platform integrates with Illumina and Element Biosciences sequencing instruments and is supported by a Certified Service Provider network.
Differentiator
Problem solved
Functional benefit
Products and services
- duet multiomics solution evoC A true 6-base genome sequencing kit that distinguishes all four canonical DNA bases (A, C, G, T) plus 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) at single-base resolution from a single 5ng DNA sample in a single experiment, sold in 8-reaction (product code 6205) and 24-reaction (product code 6206) kit formats and bundled with duet software; targeted at cancer, neurodegeneration, ageing and liquid biopsy researchers on Illumina or Element Biosciences sequencers.
- duet multiomics solution +modC A 5-base genome sequencing kit that measures the four canonical bases without ambiguity in C or T calls plus modified cytosine (modC) using existing NGS pipelines phased within a single read, requiring only 10ng of DNA input; available in 8-reaction (product code 5205) and 24-reaction (product code 5206) kit formats with duet software, intended for epigenetic and genetic analysis on standard sequencers.
- modality XPLR High-performance, low-code analysis software for 6-base sequencing data that transforms raw sequencing counts into multiomic model-ready features with biological QC, differential methylation analysis, feature extraction and publication-ready visualizations; bundled with duet kits and also available as a standalone recurring subscription, running on a standard laptop.
- duet software Post-sequencing analysis software that processes sequencing data through read resolution, genome alignment, variant calling and epigenetic quantification, providing complete genetic data plus methylation data at single-base resolution; deployable on-premises or in the cloud and bundled with the duet multiomics solution kits.
- Custom Solutions Tailored workflow, kit and integrated solution development service offering purpose-built assay development, tailored product optimization, flexible formatting, and co-branded or white-label commercial products built around biomodal's multiomics technology for partners and large customers.
- duet UDIs (Unique Dual Indexes) Unique dual index kits for multiplexing samples on the duet multiomics workflow, available in 1-8 (product code 4103), 1-24 (product code 4102) and 1-96 (product code 4104) reaction kit sizes as a complementary reagent for kit customers.
Quantifiable outcome
- AUC of 0.95 for stage I colorectal cancer detection from liquid biopsy using 6-base sequencing
- +3 more outcomes
Companies that use biomodal
Customer profileNamed customers9 records
Segments7 records
Ideal customer profiles3 records
biomodal technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability3 records
Feature6 records
biomodal partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- Element Biosciencescorebiomodal announced at AGBT 2026 General Meeting that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 and AVITI sequencing instruments. Validation conducted at the University of Minnesota Genomics Center. The collaboration enables complete methylation detection on Element platforms, combining biomodal's 5-base and 6-base sequencing solutions with Element's high-throughput sequencing systems for streamlined end-to-end workflows.
- University of Minnesota Genomics CentersupportingValidation partner for Element Biosciences compatibility testing. Conducts validation studies to verify duet multiomic solutions work correctly on Element sequencing instruments.
- Zymo ResearchcoreZymo Research partnered with biomodal to integrate biomodal's multiomics technology into Zymo's NGS Services platform, enabling analysis of multiple DNA modifications from a single library. Collaboration aims to advance epigenetics research and promote insights into gene regulation, disease mechanisms, and cellular function. Combined offering accelerates research in oncology, neurobiology, aging, and precision medicine.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
biomodal competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
biomodal social profiles
Digital presencebiomodal financial estimates
Financial estimateRevenue estimate
Valuation estimate
biomodal leadership team
Management profileNumber of profiles
Profiles11 records
biomodal funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
biomodal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about biomodal
What does biomodal do?
biomodal develops and sells the duet multiomics solution, a sequencing chemistry and software platform that simultaneously reads the four canonical DNA bases together with the epigenetic modifications 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) from a single low-input DNA sample in a single workflow. Its commercial products are the duet evoC kit (true 6-base genome, 5ng input) and the duet +modC kit (5-base genome, 10ng input), supported by duet software for post-sequencing analysis and the modality XPLR software for multiomic data exploration, all compatible with Illumina and Element Biosciences sequencers.
Is biomodal a public or private company?
biomodal is a private company. It is classified as venture growth investor backed and is currently operating.
When was biomodal founded?
biomodal was founded in 2013. It employs 51 to 100 people.
Where is biomodal based?
biomodal is headquartered in Chesterford, United Kingdom, in the Europe region.
How does biomodal make money?
Five revenue lines are on record. duet evoC product sales are the primary driver. The others are duet +modC product sales, modality XPLR software, custom solutions and OEM partnerships and certified Service Provider network.
Does biomodal have an API?
No public API is recorded for biomodal.
What industry is biomodal in?
biomodal's product category is DNA Sequencing Tools. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 334516 and its SIC code is 3826.